Pfizer, Moderna will rake in a combined $93 billion next year on COVID-19 vaccine sales: reportnews2021-10-18T14:23:32+00:00October 18th, 2021|Fierce Pharma|
FDA knocks down United Therapeutics’ dry powder Tyvaso application on manufacturing issuenews2021-10-18T14:04:43+00:00October 18th, 2021|Fierce Pharma|
Revance’s Botox rival turned away by FDA after inspectors flagged manufacturing ‘deficiencies’news2021-10-18T13:15:29+00:00October 18th, 2021|Fierce Pharma|
Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?news2021-10-16T16:55:37+00:00October 16th, 2021|Fierce Pharma|
Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’news2021-10-15T19:25:12+00:00October 15th, 2021|Fierce Pharma|
Bayer, CureVac part ways on COVID-19 vaccine: reportsnews2021-10-15T14:43:52+00:00October 15th, 2021|Fierce Pharma|
Despite Merck’s oral COVID-19 drug, antibodies by Regeneron, GSK and others still have billions in sales ahead: analystnews2021-10-15T14:08:27+00:00October 15th, 2021|Fierce Pharma|
Johnson & Johnson puts talc headache into bankruptcy; plaintiffs will contest the ploynews2021-10-15T13:02:23+00:00October 15th, 2021|Fierce Pharma|
Fierce Pharma Asia—Takeda’s cell, gene therapy deals; BMS-BeiGene Abraxane brawlnews2021-10-15T09:47:37+00:00October 15th, 2021|Fierce Pharma|
FDA panel backs half-dose Moderna booster for the elderly and others at high risknews2021-10-14T21:00:44+00:00October 14th, 2021|Fierce Pharma|
